KEYTRUDA POWDER (pembrolizumab)
MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Indication
PD-L1 positive squamous cell carcinoma of head and neck
PD-L1 positive squamous cell carcinoma of the head and neck is an epithelial malignancy arising from the mucosal linings of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, and sinonasal tract. Read more about PD-L1 positive squamous cell carcinoma of head and neck
3 drugs 1 manufacturers
Drugs that treat it
Common PD-L1 positive squamous cell carcinoma of head and neck therapies.
KEYTRUDA (pembrolizumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+33
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with PD-L1 positive squamous cell carcinoma of head and neck preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPD-L1 positive squamous cell carcinoma of the head and neck is an epithelial malignancy arising from the mucosal linings of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, and sinonasal tract.
It is pathologically characterized by the immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor-infiltrating lymphocytes, and histiocytes, typically defined by a combined positive score or tumor proportion score above a validated threshold.
This biomarker positivity reflects an immunosuppressive tumor microenvironment where PD-L1 engages PD-1 receptors on cytotoxic T cells, promoting immune evasion and tumor survival.
Commonly associated with tobacco, alcohol exposure, or oncogenic human papillomavirus infection, this molecularly defined subset frequently presents as locally aggressive or recurrent disease with a heightened susceptibility to targeted immune checkpoint inhibition.
- nih.gov
PD-L1 positive squamous cell carcinoma of the head and neck is an epithelial malignancy arising from the mucosal linings of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, and sinonasal tract This biomarker positivity reflects an immunosuppressive tumor microenvironment where PD-L1 engages PD-1 receptors on cytotoxic T cells, promoting immune evasion and tumor survival Commonly associated with tobacco, alcohol exposure, or oncogenic human papillomavirus infection, this...
- bmj.com
PD-L1 positive squamous cell carcinoma of the head and neck is an epithelial malignancy arising from the mucosal linings of the upper aerodigestive tract, including the oral cavity, pharynx, larynx, and sinonasal tract
- fda.gov
It is pathologically characterized by the immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor-infiltrating lymphocytes, and histiocytes, typically defined by a combined positive score or tumor proportion score above a validated threshold
- fda.gov
It is pathologically characterized by the immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor-infiltrating lymphocytes, and histiocytes, typically defined by a combined positive score or tumor proportion score above a validated threshold
- arupconsult.com
It is pathologically characterized by the immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor-infiltrating lymphocytes, and histiocytes, typically defined by a combined positive score or tumor proportion score above a validated threshold
- nih.gov
It is pathologically characterized by the immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor-infiltrating lymphocytes, and histiocytes, typically defined by a combined positive score or tumor proportion score above a validated threshold
- nih.gov
This biomarker positivity reflects an immunosuppressive tumor microenvironment where PD-L1 engages PD-1 receptors on cytotoxic T cells, promoting immune evasion and tumor survival
- asco.org
Commonly associated with tobacco, alcohol exposure, or oncogenic human papillomavirus infection, this molecularly defined subset frequently presents as locally aggressive or recurrent disease with a heightened susceptibility to targeted immune checkpoint inhibition
Personalize your experience
Follow PD-L1 positive squamous cell carcinoma of head and neck and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.